| Hazard Information | Back Directory | [Uses]
Citatuzumab bogatox (VB6-845) is recombinant immunotoxin that composed of Fab fragment of humanized antibody targeting EpCAM and a modified cytotoxin bouganin. Citatuzumab bogatox binds to and selectively induces apoptosis in EpCAM-positive cell lines and shows good activity in EpCAM-positive human tumour xenograft models[1][2][3]. | [in vivo]
Citatuzumab bogatox (10, 20 mg/kg; i.v./i.p.) inhibits growth of tumor in mice[1].
Citatuzumab bogatox (10, 20 mg/kg) are well tolerated by mice without any significant weight loss[1]. | Animal Model: | Female CB.17 SCID mice (~20 g; OVCAR-3 Xenograft model)[1]. | | Dosage: | 10, 20 mg/kg | | Administration: | Tail vein (until day 26 when due to tail swelling, route of administration was changed to intraperitoneal for the remaining 7 doses); single daily for 5 consecutive days for 3 weeks and then received maintenance dosing on Monday and Friday for 4 weeks. | | Result: | Showed an average of 40 mm3 (control group was 750 mm3) on day 75, and with 3/15 mice being tumor free, when at 10 mg/kg.
Almost completely inhibited tumour growth when at 20 mg/kg.
|
| [References]
[1] Cizeau J, et al. Engineering and biological characterization of VB6-845, an anti-EpCAM immunotoxin containing a T-cell epitope-depleted variant of the plant toxin bouganin. J Immunother. 2009 Jul-Aug;32(6):574-84. DOI:10.1097/CJI.0b013e3181a6981c
[2] Eyvazi S, et al. Antibody Based EpCAM Targeted Therapy of Cancer, Review and Update. Curr Cancer Drug Targets. 2018;18(9):857-868. DOI:10.2174/1568009618666180102102311
[3] Bruce VJ, et al. Minimalist Antibodies and Mimetics: An Update and Recent Applications. Chembiochem. 2016 Oct 17;17(20):1892-1899. DOI:10.1002/cbic.201600303 |
|
| Company Name: |
Biolab Reagents
|
| Tel: |
18108604356 18108604356 |
| Website: |
www.biolabreagent.com/ |
|